The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. Issue 3 (9th September 2021)

• Record Type: Journal Article
• Authors: Stein, Dan J.; Craske, Michelle G.; Rothbaum, Barbara O.; Chamberlain, Samuel R.; Fineberg, Naomi A.; Choi, Karmel W.; de Jonge, Peter; Baldwin, David S.; Maj, Mario
• Is Part Of: World psychiatry. Volume 20:Issue 3(2021)
• Page Start: 336
• Page End: 356
• Publication Date: 2021-09-09
• Subjects: Anxiety -- anxiety and related disorders -- obsessive‐compulsive disorder -- post‐traumatic stress disorder -- personalization of treatment -- symptom profile -- clinical subtypes -- severity -- neurocognition -- functioning -- quality of life -- personality traits -- psychiatric antecedents -- psychiatric comorbidities -- physical comorbidities -- family history -- early environmental exposures -- recent environmental exposures -- protective factors -- dysfunctional cognitive schemas; Psychiatry -- Periodicals; Mental illness -- Periodicals; 616.89005
• DOI: 10.1002/wps.20919
• Languages: English
• ISSNs: 1723-8617

Abstract

Abstract : The clinical construct of "anxiety neurosis" was broad and poorly defined, so that the delineation of specific anxiety disorders in the DSM‐III was an important advance. However, anxiety and related disorders are not only frequently comorbid, but each is also quite heterogeneous; thus diagnostic manuals provide only a first step towards formulating a management plan, and the development of additional decision support tools for the treatment of anxiety conditions is needed. This paper aims to describe systematically important domains that are relevant to the personalization of management of anxiety and related disorders in adults. For each domain, we summarize the available research evidence and review the relevant assessment instruments, paying special attention to their suitability for use in routine clinical practice. We emphasize areas where the available evidence allows the clinician to personalize the management of anxiety conditions, and we point out key unmet needs. Overall, the evidence suggests that we are becoming able to move from simply recommending that anxiety and related disorders be treated with selective serotonin reuptake inhibitors, cognitive‐behavioral therapy, or their combination, to a more complex approach which emphasizes that the clinician has a broadening array of management modalities available, and that the treatment of anxiety and related disorders can already be personalized in a number of important respects.